Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.

Authors:

Saad F, Roubaud G, Procopio G, et al.

Year

2020

Conference

ASCO Annual Meeting

Location

Virtual

Start Date

May 29

End Date

Jun 2